David James Pinato

83PUBLICATIONS
566CO-AUTHORS
Molecular targetsHaematological tumoursSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (83)

|Aug 11, 2026
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

|Aug 05, 2026
In-depth characterisation of the tumour microenvironment reveals HHV-8-dependent immune regulation in HIV-associated and classic Kaposi sarcoma.

|Jun 04, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Feb 12, 2026
Antibiotic Use Linked to Worse Outcomes in Patients With Gastrointestinal and Liver Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis.

Mohammad Saeid Rezaee-Zavareh, Hamidreza Karimi-Sari, Peyvand Parhizkar Roudsari

Pageof 14

Frequent Collaborators

23 joint publications

Alessio Cortellini

13 joint publications

Antonio D'Alessio

7 joint publications

Lorenza Rimassa

6 joint publications

Matthias Pinter